The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(This story corrects a typo in the first paragraph)

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)